Herzlich Willkommen

Die Zeitschrift Klinische Pädiatrie erscheint 7-mal jährlich und veröffentlicht Beiträge aus dem Gebiet der (klinischen) Pädiatrie und deren Grenzgebiete in deutscher und englischer Sprache. Die Zeitschrift wird in allen wichtigen internationalen Zitationsdiensten geführt.

Wissenschaftspreis

Die Gewinner des Wissenschaftspreises Klinische Pädiatrie stehen fest. Lesen Sie hier mehr.

DOI 10.1055/s-00000034

Klinische Pädiatrie

S-I

Single cell RNA-sequencing of the Hodgkin lymphoma tumor microenvironment

Deregulated transcription factor networks in HRS cells

RNA-seq analysis of plasmatic exosomal miRNAs in pediatric Hodgkin Lymphoma

Molecular Mechanisms in the Pathogenesis of Composite Lymphomas

Genomic Landscape of Reed-Sternberg Cells of Hodgkin Lymphoma from Children, Adolescents, and Young Adults

A specific chromatin structure and increased RUNX3 expression contribute to the Hodgkin/Reed-Sternberg cell-specific phenotype

Circulating tumor DNA in Genetic Profiling and Monitoring of Pediatric Hodgkin Lymphoma

Nachruf

Im Gedenken an Professor Dr. med. Ludwig Gortner

S-II

Immune Checkpoint Inhibition and Drug Targets

Immune checkpoint inhibition in lymphoma

Hodgkin lymphoma microenvironment: cross talk between HRS cells and the rosetting T cells

Interactive Case Presentation

Brentuximab Vedotin and Rituximab with Reduced Toxicity Chemotherapy in Children, Adolescents and Young Adults with Newly Diagnosed Hodgkin Lymphoma

Nivolumab monotherapy in childhood refractory and relapsed Hodgkin’s lymphoma

A randomized Phase III trial of Brentuximab vedotin (Bv) for de novo High-Risk Classical Hodgkin Lymphoma (cHL) in children and adolescents - Study Design and Incorporation of secondary endpoints in Children’s Oncology Group (COG) AHOD1331

Phase 2, open-label study of pembrolizumab in children and young adults with newly diagnosed classical hodgkin lymphoma (cHL) with slow early response (SER) to frontline chemotherapy: KEYNOTE-667

S-III

Global Experiences

Evolution of CLEHOP as a Cooperative Group and its Experience with the Latin American LH Protocol

Hodgkin lymphoma: Trials and tribulations in a middle income country. The first inclusive prospective paediatric cancer study in South Africa

Interactive Case Presentation

Epstein Barr Virus in children and adolescents with classical Hodgkin Lymphoma: analysis of a cohort of 299 patients

Lymphocyte-Predominant Hodgkin Lymphoma Variant: Long Term Outcome. Data From The Lh-2004 Protocol Of The Italian Association Of Pediatric Hematology And Oncology (Aieop)

The GATLA (Argentinian Collaborative Group) experience through international cooperation in Pediatric Hodgkin Lymphoma (HL)

Assessment of Epstein-Barr Virus (EBV) status and its impact on outcomes in intermediate and high-risk childhood classic Hodgkin Lymphoma (cHL) treated at a tertiary cancer center in India

Pediatric Hodgkin lymphoma: Characteristics, stratification,treatment and survival at a single institute in Lima-Perú.

Clinical course and prognosis of children with Hodgkin Lymphoma in Central and Southern Mexico areas. Results of the Mexican Association of Pediatric Hematology and Oncology

PW I-V

Guided Poster Walk

3′ untranslated region A>C (rs3212227) polymorphism of Interleukin 12B gene as a potential risk factor for Hodgkin’s lymphoma in Brazilian children and adolescents

Assessment of tumor antigen specific T cell immunity and cytokine milieu at diagnosis in patients with high risk Hodgkin Lymphoma treated on Children’s Oncology Group trial AHOD1331

The prognostic value of HLA-G genetic marker in paediatric Hodgkin lymphoma patients enrolled in the italian AIEOP-LH2004 trial

TARC is a specific and sensitive serum marker for classical Hodgkin’s lymphoma in children

Comparative proteomic profiling in recurrent pediatric/adolescent Hodgkin Lymphoma

Cell-free DNA as biomarker in Hodgkin lymphoma patients

Expression of splice variants of the transcription factor ONECUT2 in Hodgkin lymphoma cells

Increased Expression of Matrix Metalloproteinases 2 and 9 as Poor Prognosis Factor for Hodgkin’s Lymphoma Patients

HLA haplotype on outcomes in pediatric Hodgkin patients enrolled in the italian AIEOP-LH2004 trial

Expression of human endogenous retroviruses and associated transcripts in Hodgkin lymphoma cells

An Intergroup Approach for Advanced Stage Classical Hodgkin Lymphoma (cHL) in Adolescents and Young Adults (AYA): SWOG S1826.

Phase I study of brentuximab vedotin (SGN-35) in Japanese children with relapsed or refractory CD30-positive Hodgkin’s lymphoma or systemic anaplastic large cell lymphoma

Prognostic Value of Interim and End of Treatment PET-CT Scan Results in Pediatric Hodgkin Lymphoma

A Case Report of Neutropenic Enterocolitis in Armenia

Retrospective Analysis of Baseline Prognostic Factors On the Outcome of Pediatric Hodgkin Lymphoma in a Tertiary Cancer Centre

Nodular Lymphocyte Predominant Hodgkin Lymphoma - experience of Polish Pediatric Leukemia/Lymphoma Study Group

Real-life experience of multisciplinary pediatric lymphoma tumor board: decision’s impact on Hodgkin Lymphoma treatment choice and results

Hodgkin Lymphoma Cases in Mongolia

Result of therapy for Hodgkin Lymphoma (HL): a report from the Chilean pediatric National Cancer Program (PINDA)

Hodgkin’s disease in children in Moroccan Hospital

High response rate to combined chemotherapy avoiding radiotherapy in children and adolescents with classical Hodgkin lymphoma. Preliminary results of GALOP LH 2017 Protocol

Hodgkin lymphoma: results observed in an oncological center of the Ecuadorian Andes. Series of cases with follow-up

Pediatric lymphocyte-predominant Hodgkin lymphoma: Review of Spanish patients between November-2007 and October-2019

Clinical trial of Childhood, Adolescent and Young Adult Hodgkin Lymphoma in Japan

Anemia: frequency and type in pediatric patients with Hodgkin’s lymphoma

Prognostic model for pediatric Hodgkin Lymphoma patients in developing country

Is it Possible to Work together in Latin America? The Latin American Consortium (CLEHOP) experience with Hodgkin Lymphoma (HL)

S-IV

International Trial Workshop

Global nLPHL trial proposal

Proposal for a global Grey Zone Lymphoma Registry

Regulatory Aspects roundtable discussion

S-V

Relapse treatments

Novel agents beyond Immunotherapy

Risk and Response adapted salvage treatments in R/R Classical HL in children and young people – European guidelines

Interactive Case Presentations, Panel discussion, Scenarios

Response rates, long term outcomes and toxicity profile of Gemcitabine and Vinorelbine based outpatient chemotherapy regimen in primary progressive and relapsed pediatric Hodgkin Lymphoma

Brentuximab vedotin plus bendamustine in relapsed and refractory classical Hodgkin lymphoma in children, adolescents and young adults: a single centre experience

A New Model for Stratification of Treatment Intensity in Relapsed Pediatric Hodgkin Lymphoma

Outcome of Pediatric Relapsed/Refractory Hodgkin Lymphoma Patients in 2 different Latin American Settings: AHOPCA (Asociación de Hemato-Oncología Pediátrica de Centro América) and GATLA (Grupo Argentino de Tratamiento de Leucemia Aguda)

S-VI

Cellular therapies

T cell therapies to overcome the tumor microenvironment in HL

CD30 CAR T for HL and ALCL

Study on primary immunodeficiencies & EBV- induced HL

Interactive Case Presentation

Tumor associated antigen specific T cells for Hodgkin Lymphoma

S-VII

Contemporary Radiotherapy across the PHL Working Groups

Panel Case Discussions (Low risk, Int risk, High risk)

Are event-free survival and freedom-from progression compromised by reduced radiation doses fields? Comparison between the results of the AIEOP (Italian Association of Pediatric Hematology and Oncology) LH-2004 & MH96 Protocols

Reduction in Cardiac Radiation Dose Among Children Receiving Mediastinal RT: Comparison of Involved-Site vs Involved-Field RT Delivered in Three Children’s Oncology Group Trials

Cost-effectiveness of proton therapy for young adults with mediastinal lymphoma: analysis of an institutional cohort

Proton-Radiotherapy for treatment of Hodgkin’s disease of minor or adolescent patients

S-VIII

Survivorship and Aftercare

Fertility preservation

Late health outcomes

Interactive Case Presentation

Subsequent Malignant Neoplasms Among Children and Adolescents with Hodgkin Lymphoma Treated with Response-Adapted Therapy: A Report from the Children’s Oncology Group Study AHOD0031

Late effects after Hodgkin lymphoma in childhood and adolescence – results of the German Survivor Cohort after 22 years of follow-up

Hyperlipoproteinemia, insulin resistance and metabolic syndrome in long-term survivors of Hodgkin lymphoma during childhood and adolescence

Chemotherapy-induced loss of protective antibody titers against commonest vaccine-preventable infections in patients with pediatric Hodgkin lymphoma

PW VI-X

Guided Poster Walk

PW VI-X-01 Relapse-localization in pediatric patients with Hodgkin lymphoma

BV-DHAP as salvage treatment for high risk adolescent Hodgkin lymphoma

Brentuximab vedotin (BV) in recurrent and refractory Hodgkin Lymphoma (HL) in children. Experience of Polish Pediatric Leukemia/Lymphoma Study Group

Cardiac substructures dose sparing in pediatric Hodgkin’s lymphoma

Dosimetric comparison of active scanning Proton Therapy and Helical Tomotherapy in pediatric and adolescent Hodgkin’s lymphoma treated with tomotherapy.

Access to proton beam therapy (PBT) for patients with large mediastinal adenopathy (LMA)

Long term effects of consolidative radiotherapy in Hodgkin’s Lymphoma patients at Single institution

Hyperthyroidism as late adverse effect of treatment for Hodgkin lymphoma

16 May 2020

Staging Evaluation and Response Criteria Harmonization (SEARCH) for CAYAHL

E-lesions with an emphasis on bone involvement

Nodular sclerosis lymphoma - the new radiology sign

Creating an International Hodgkin Lymphoma Data Commons

Methodological comparison of volumetric analysis on FDG PET in pediatric Hodgkin Lymphoma assessed at different timing

The impact of the Point-spread-function (PSF) reconstruction on the response assessment in the Interim-PET (iPET) in Hodgkin lymphoma (HL)

Staging of Waldeyer’s ring in Pediatric and Adolescent Patients with Hodgkin’s lymphoma – Importance of multimodality imaging

Impact of central review of imaging in an FDG-PET response adapted Pediatric Hodgkin lymphoma protocol

Comparison of interim PET response to relapse vs. first-line treatment in children with classical Hodgkin lymphoma (HL) – contribution to the development of response criteria for relapsed HL

CT-morphologic vs. metabolic tumor volume in pediatric Hodgkin-Lymphoma - A comparison of 19 different semiautomatic delineation methods

S-X

HL biology in adolescents and young adults

Navigating Survivorship for AYAs with Hodgkin Lymphoma

Simulation modelling to delineate long term patient outcome in AYA HL

Outcomes by age in pediatric and adolescent patients treated for de novo Hodgkin lymphoma on contemporary Children’s Oncology Group trials

Thieme Newsletter

Jetzt kostenlos anmelden

Melden Sie sich jetzt kostenlos zum Newsletter an und verpassen Sie keine Neuigkeiten mehr!

Jetzt abonnieren ... zum günstigen Einstiegspreis!

Ansprechpartner

Kundenservice Fon:+49 711 8931-321 Fax:+49 711 8931-422 Kundenservice

Redaktion E-Mail schreiben

Buchtipps Pädiatrie

Differenzialdiagnosen in der Kinder- und Jugendmedizin

Robert PloierDifferenzialdiagnosen in der Kinder- und Jugendmedizin

EUR [D] 89,99Zum Warenkorb hinzufügenInkl. gesetzl. MwSt.

Praktische Pneumologie in der Pädiatrie - Diagnostik

Matthias Griese, Thomas Nicolai, Robert Dalla Pozza, Christoph Döhlemann, Richard de la ChauxPraktische Pneumologie in der Pädiatrie - Diagnostik

Rationale Differenzialdiagnostik

EUR [D] 24,99Zum Warenkorb hinzufügenInkl. gesetzl. MwSt.

Drucken Top